SCHEMBL21261016

SCHEMBL21261016

CC1(C)Cc2c(sc(NC(=O)c3ccncn3)c2C(=O)O)C(C)(C)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 2/20 0.60
▸ KMT2A Q03164 5/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ MAPT P10636 4/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ P2RX7 Q99572 1/20 0.38
▸ RAB7A P51149 1/20 0.37
▸ CFTR P13569 4/20 0.36
▸ FABP4 P15090 1/20 0.36
▸ FABP5 Q01469 1/20 0.36
▸ GRM4 Q14833 1/20 0.36
▸ RORC P51449 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NOD2 Q9HC29 1/20 0.35
▸ BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247200 0.86 PTPN1 (0.61) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21247258 0.81 RAB7A (0.57) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL21247337 0.80 PTPN1 (0.68) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21247234 0.78 PTPN1 (0.64) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21261018 0.75 PTPN1 (0.60) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21260934 0.74 PTPN1 (0.73) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21247303 0.74 PTPN1 (0.59) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21247155 0.74 PTPN1 (0.56) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21247100 0.74 ALDH1A1 (0.52) PTPN1KMT2AMEN1ALDH1A1MAPT
SCHEMBL21261013 0.74 PTPN1 (0.53) PTPN1KMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
CN-111954668-A Fused thiophene derivative and use thereof 埃尼奥制药公司 2020-11-17 — — CN disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH PTPN1 1639/4885KMT2A 3454/4885MEN1 3538/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH PTPN1 1639/4885KMT2A 3454/4885MEN1 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback